v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenues:    
Total revenues $ 897,841 $ 901,983
Operating expenses:    
Cost of product sales (excluding amortization of acquired developed technologies) 104,620 95,487
Selling, general and administrative 514,013 351,712
Research and development 180,652 222,847
Intangible asset amortization 154,448 155,730
Acquired in-process research and development 0 10,000
Total operating expenses 953,733 835,776
Income (loss) from operations (55,892) 66,207
Interest expense, net (53,706) (66,116)
Foreign exchange loss (213) (1,693)
Loss before income tax (benefit) expense and equity in loss of investees (109,811) (1,602)
Income tax (benefit) expense (17,812) 11,669
Equity in loss of investees 542 1,347
Net loss $ (92,541) $ (14,618)
Net loss per ordinary share:    
Basic (in dollars per share) $ (1.52) $ (0.23)
Diluted (in dollars per share) $ (1.52) $ (0.23)
Weighted-average ordinary shares used in per share calculations - basic (in shares) 60,979 62,537
Weighted-average ordinary shares used in per share calculations - diluted (in shares) 60,979 62,537
Product sales, net    
Revenues:    
Total revenues $ 839,418 $ 842,102
Royalties and contract revenues    
Revenues:    
Total revenues $ 58,423 $ 59,881